Compare MNDO & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MNDO | NOTV |
|---|---|---|
| Founded | 1995 | 1974 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.8M | 23.0M |
| IPO Year | 2000 | 1997 |
| Metric | MNDO | NOTV |
|---|---|---|
| Price | $1.21 | $0.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 28.5K | ★ 463.7K |
| Earning Date | 03-03-2026 | 02-05-2026 |
| Dividend Yield | ★ 18.18% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | $19,770,000.00 | ★ $513,024,000.00 |
| Revenue This Year | N/A | $6.49 |
| Revenue Next Year | N/A | $4.95 |
| P/E Ratio | $8.64 | ★ N/A |
| Revenue Growth | N/A | ★ 4.54 |
| 52 Week Low | $0.98 | $0.47 |
| 52 Week High | $2.13 | $4.80 |
| Indicator | MNDO | NOTV |
|---|---|---|
| Relative Strength Index (RSI) | 49.59 | 35.41 |
| Support Level | $1.11 | $0.56 |
| Resistance Level | $1.23 | $0.58 |
| Average True Range (ATR) | 0.04 | 0.04 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 42.86 | 11.07 |
MIND C.T.I. Ltd develops, manufactures, markets, and implements real-time and off-line convergent billing and customer care software solutions. It derives revenue from the sale of software products and services in two reportable segments, namely Billing and Related Services, which derives key revenue, and Messaging. The company has three product lines: Product Line A- billing and customer care solutions for service providers; Product Line B - call accounting and call management solutions for enterprises; and Product Line C - mobile messaging, communication, and payment solutions. Geographically, the company operates in the Americas, Europe, Asia Pacific and Africa, and Israel. It earns maximum revenue from Europe.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.